KinCon biolabs provides a patented target-protein engagement reporter technology to accelerate or enable the identification of new types of more efficient drug candidates at early stages of the drug discovery pipeline.
company data |
|
| employees: | 6 - 10 |
| legal form: | Gesellschaft mit beschränkter Haftung |
| commercial register number: | 578388x |
| founding date: | 2022 |
| Mitglied im Cluster: | |
references: |
|
| Top 20 pharma companies, Immunic AG | |
products and services: |
|
| We engineer cell-based target engagement reporters for in-house drug profiling (efficacy, specificity, potency) to enable or accelerate preclinical stages of drug discovery. | |
research and innovation |
|
|
FFG Life Science Austria Project Health Hub Tirol Project Industrial PhD Project (Land Tirol, FFG) |
|
contact information |
|
| street: | Innrain 66 |
| ZIP code: | 6020 |
| city: | Innsbruck |
| country: | Österreich |
| phone: | +43 676 465 3619 |
| email: | office@kincon-biolabs.eu |
| website: | https://www.kincon-biolabs.eu |
|
contact: |
Dr. Eduard Stefan |
| function: | |
| phone: | +43 676 465 3619 |
| email: | eduard.stefan@kincon-biolabs.eu |
|
contact: |
Philipp Tschaikner |
| function: | |
| phone: | +43 676 464 0767 |
| email: | philipp.tschaikner@kincon-biolabs.eu |
-
competences and specialization
- biotechnology
- cell-based target engagement
- drug efficacy